The discovery and development of zileuton: An orally active 5-lipoxygenase inhibitor
1992; Elsevier BV; Volume: 14; Issue: 3 Linguagem: Inglês
10.1016/0192-0561(92)90182-k
ISSN1879-3495
AutoresRandy L. Bell, Patrick Young, Daniel H. Albert, Carmine Lanni, James B. Summers, Dee W. Brooks, Paul Rubin, G.W. Carter,
Tópico(s)Synthesis and Reactions of Organic Compounds
ResumoThe enzyme 5-lipoxygenase is a key target in the effort to discover drugs which inhibit the pathophysiology associated with the formation of leukotrienes. The research efforts of these laboratories have focused on the discovery of direct enzyme inhibitors of 5-lipoxygenase. In particular, compounds with hydroxamate or N-hydroxyurea functionalities have proven to be potent inhibitors of leukotriene biosynthesis in vitro and more importantly in vivo. One of these compounds, zileuton (N-(1-benzo-[b]-thien-2-ylethyl)-N-hydroxyurea) has been shown recently to be an effective leukotriene inhibitor in man. The critical approaches and breakthroughs in the discovery and development of zileuton are described. In addition, some recent results with zileuton in animals and man are detailed.
Referência(s)